Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2300-2305

  Torrea, Gabriela ^a   Coeck, Nele ^a   Desmaretz, Christel ^a   Van De Parre, Tim ^a   Van Poucke, Tijs ^a   Lounis, Nacer ^b   de Jong, Bouke C ^a,c,d   Rigouts, Leen ^a,e  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c NEW YORK UNIVERSITY   (United States)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Drug susceptibility testing; Epidemiological cut offs; MGIT960; Multidrug resistance

Indexed keywords

AGAR; BEDAQUILINE; ISONIAZID; CULTURE MEDIUM; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATION; BACTERIUM CULTURE; CONTROLLED STUDY; LIQUID CULTURE; MEASUREMENT REPEATABILITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUALITY CONTROL; REPRODUCIBILITY; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; EVALUATION STUDY; HUMAN; LABORATORY AUTOMATION; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTITUBERCULAR AGENTS; AUTOMATION, LABORATORY; CULTURE MEDIA; DIARYLQUINOLINES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84939488863     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv117     Document Type: Article

References (25)

1. WHO. Global Tuberculosis Report 2014. WHO/HTM/TB/2014.08. http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf.
2. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
3. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-4.
4. Huitric E, Verhasselt P, Andries K et al. In vitro antimycobacterial spectrum of diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51: 4202-4.
5. FDA. Sirturo (Bedaquiline) Product Insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf.
6. WHO. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf.
7. EUCAST. Definitions of Clinical Breakpoints and Epidemiological Cut-off Values. Clinical Breakpoints Table V.5.0. Valid From 2015-01-01. http://www.eucast.org/clinical_breakpoints/.
8. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-81.
9. Andries K, Villellas C, Coeck N et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135.
10. Somoskövi A, Bruderer V, Hömke R et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015; 45: 554-7.
11. Salfinger M, Migliori GB. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. Eur Respir J 2015; 45: 317-21.
12. Clinical and Laboratory Standards Institute. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters-Third Edition: Approved Guideline M23-A3. CLSI, Wayne, PA, USA, 2008.
13. EUCAST. Setting Breakpoints for New Antimicrobial Agents. EUCAST SOP 1.1 2013. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/EUCAST_SOPs/EUCAST_SOP_1._1_Setting_breakpoints_new_agents_1_June_2013.pdf.
14. Landis JR, Koch GG. The measurements of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
15. Lounis N, Vranckx L, Gevers T et al. Conditions affecting the minimal inhibitory concentration (MIC) of bedaquiline against Mycobacterium tuberculosis. In: Abstracts of the Forty-fifth World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Barcelona, 2014. Poster PD-723-30, p. S186. International Union Against Tuberculosis and Lung Disease (The Union), Paris, France. http://barcelona.worldlunghealth.org/programme/body/Abstract_Book_2014-Web.pdf.
16. Canetti G, FoxW, Khomenko A et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
17. Anti-Infective Drugs Advisory Committee. Anti-Infective Drugs Advisory Committee Meeting Briefing Document. TMC207 (Bedaquiline). Treatment of Patients with MDR-TB. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf.
18. Sohn H, Kil-Soo L, Young-Kwan K et al. In vivo and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria. Int J Antimicrob Agents 2008; 31: 567-71.
19. Larsen MH, Vilchèze C, Kremer L et al. Overexpression of inhA but not kasA confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 2002; 2: 453-66.
20. Wiid J, van Helden EH, Hon D et al. Potentiation of isoniazid activity against Mycobacterium tuberculosis by melatonin. Antimicrob Agents Chemother 1999; 43: 975-7.
21. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
22. Schön T, Juréen P, Ciske CG et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786-93.
23. Juréen P, Ängeby K, Sturegard E et al. Wild-type MIC distribution for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 2010; 48: 1853-8.
24. Kahlmeter G, Brown DFJ, Goldstein FW et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 2006; 12: 501-3.
25. Sturegard E, Angeby KA, Werngren J et al. Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wildtype organisms determined with BACTEC MGIT960 and Middlebrook 7H10. Clin Microbiol Infect 2015; 21: 148.e5-7.